Fincke v. Access Cardiosystems, Inc. (Access Cardiosystems, Inc.)

488 B.R. 1, 2012 WL 4482386, 2012 U.S. Dist. LEXIS 139114
CourtDistrict Court, D. Massachusetts
DecidedSeptember 26, 2012
DocketBankruptcy No. 11-40223-NMG
StatusPublished
Cited by4 cases

This text of 488 B.R. 1 (Fincke v. Access Cardiosystems, Inc. (Access Cardiosystems, Inc.)) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Fincke v. Access Cardiosystems, Inc. (Access Cardiosystems, Inc.), 488 B.R. 1, 2012 WL 4482386, 2012 U.S. Dist. LEXIS 139114 (D. Mass. 2012).

Opinion

[3]*3MEMORANDUM & ORDER

GORTON, District Judge.

This bankruptcy appeal arises from a pre-petition suit filed in the Massachusetts Superior Court by plaintiff-appellants Access Cardiosystems, Inc. (“Access”), four of its individual investors, John J. Moriarty (“Moriarty”), James A. Radley (“Rad-ley”), Richard F. Connolly, Jr. (“Connolly”) and Joseph R. Zimmel (“Zimmel”) (collectively, “the Investors”), and the corporate entities through which several of those investments were made, against defendant-appellant Randall Fincke (“Fincke”), a former Access shareholder, officer and director. The suit asserted, inter alia, violation of the Massachusetts Uniform Securities Act, M.G.L. c. 110A, § 410(a)(2) (“Section 410(a)(2)”), and breach of fiduciary duty to Access.

I. Background

In February, 2005, Access filed a voluntary petition seeking relief under Chapter 11 of the United States Bankruptcy Code and the action was subsequently transferred to the United States Bankruptcy Court for the District of Massachusetts. The Bankruptcy Court ultimately determined that Fincke breached certain of his fiduciary duties to Access and, in one instance, violated Section 410(a)(2). The plaintiff-appellants sought approximately $20.8 million in damages for Fincke’s violation of Section 410(a)(2) but were awarded only $1.5 million and were denied attorneys fees.

Currently before the Court are cross-appeals of that determination. The appeals were filed, and thus docketed, separately but were consolidated in January, 2012 by order of this Court. Fincke contests the finding of liability under Section 410(a)(2) and the award of any damages to the plaintiff-appellants. The plaintiff-appellants, in turn, contest the damages award, which they perceive to be erroneously low, and the denial of their attorneys fees.

A. Access and its Investors

The facts and proceedings of this interminable case have been exhaustively recounted by the Bankruptcy Court on numerous occasions. See, e.g., In re Access Cardiosystems, Inc., 340 B.R. 127 (Bankr. D.Mass.2006) (“Access I”); In re Access Cardiosystems, Inc., 404 B.R. 593 (Bankr. D.Mass.2009) (“Access II”); In re Access Cardiosystems, Inc., 438 B.R. 16 (Bankr. D.Mass.2010) (“Access III”); In re Access Cardiosystems, Inc., 460 B.R. 67, 83-84 (Bkrtcy.D.Mass.2011) (“Access IV”). Accordingly, the Court will rehearse the facts only as necessary for purposes of the instant appeal.

Fincke formed Access in 2000 to develop, market and sell a portable automated external defibrillator (“the Access AED”). Between 2001 and 2005, the Investors invested approximately $20.8 million in the company through various loans and stock purchases. In the spring of 2001, Access received its first outside infusion of capital from Moriarty, Fincke’s personal friend, in the amount of $50,000. Moriarty made two subsequent investments of $1 million and $500,000 in July and December, 2001, respectively. Fincke also solicited an investment of $500,000 from Connolly, another personal acquaintance, in November, 2001.

By the beginning of 2002, the Access AED had evolved considerably. A provisional patent application in the United States Patent and Trademark Office (“the PTO”) had been filed to cover the Access AED technology. Access had completed its required industry standard certification and was awaiting approval to market and sell its products in Europe. The Europe[4]*4an market was responding positively to the Access AED even before formal approval and, in February, 2002, Access began signing distribution agreements with various European distributors. In April, 2002, Moriarty and Connolly each invested an additional $800,000 in Access and the Access AED received approval for European sales and marketing.

Access continued to struggle, however, to pay past-due vendor accounts and to secure the raw materials necessary to manufacture the Access AED and thus solicited further capital investment. Moriarty and Connolly made additional investments in the company in May and June, 2002. Also around that time, Connolly solicited an investment in Access from Radley, his personal friend. After meeting with Fincke, Radley invested $2 million in Access in June, 2002.

In July, 2002, before Access had obtained FDA approval to market and sell its defibrillator in the United States, Fincke received a letter from an attorney representing Philips Electronics (“Philips”). The letter claimed, based on Philip’s investigation, that the soon-to-be-released Access AED infringed on at least one of nine patents owned by Philips. Fincke testified that he immediately forwarded the letter to corporate counsel, Michael Elefante (“Elefante”), who in turn forwarded it to Access’s patent counsel, Mark Pandiscio (“Pandiscio”). Pandiscio responded to Philips in September, 2002, requesting clarification of the specific patents and claims alleged to be infringed and proposed licensing terms.

Philips did not respond until February, 2003. In the meantime, Fincke reviewed the patents himself and concluded there were no serious infringement issues. Pan-discio testified before the Bankruptcy Court that Fincke never asked him for a formal opinion as to whether the Access AED infringed any of Philips’ listed patents or any other patents but recalled that he had discussed changing the label with Fincke and a mechanical designer.

Access received FDA approval to market and sell the Access AED in the United States in August, 2002. On August 30, 2002, Pandiscio filed with the PTO both a Non-Provisional Patent Application for the Access AED and an International Patent Application covering the Access AED technology. Shortly thereafter, Access began to sell its products in Europe.

Almost immediately, working capital constraints at Access began taking a toll. In order to obtain additional investments, Fincke, together with Access’s management team and Elefante, prepared an investor letter and a business plan dated October, 2002 (“the October, 2002 business plan”). That business plan detailed various aspects the company’s business, past performance and predicted performance. Fincke did not prepare the entire plan but contributed to its content and approved it prior to dissemination.

The October, 2002 business plan contained, in pertinent part, sections titled “Risk Factors” and “Litigation” both of which disclosed a patent-infringement lawsuit brought against Access by Cardiac Sciences but did not disclose the receipt of the letter from Philips. The plan stated:

Many U.S. and foreign patents have been issued to Access’s competitors with respect to AED’s and their constituent components. Access has been advised by its patent counsel that its product does not infringe any patents known to him. However, there can be no assurance that that opinion is correct in all respects.

Each of the then-current investors, Connolly, Moriarty and Radley, received a copy of the plan. Zimmel, a potential in[5]*5vestor introduced to Access by a company manager, also received a copy of the October, 2002 business plan shortly after it was issued. After a meeting with Fincke, Zim-mel contributed $2 million to the company in three tranches: a $1 million stock purchase in October, 2002, a $500,000 stock purchase in November, 2002, and a $500,000 loan in December, 2002.

Notwithstanding those investments, the company continued to struggle.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
488 B.R. 1, 2012 WL 4482386, 2012 U.S. Dist. LEXIS 139114, Counsel Stack Legal Research, https://law.counselstack.com/opinion/fincke-v-access-cardiosystems-inc-access-cardiosystems-inc-mad-2012.